Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.73 - $1.5 $35,198 - $72,325
-48,217 Reduced 2.0%
2,367,511 $1.78 Million
Q1 2024

May 15, 2024

SELL
$1.01 - $1.4 $43,662 - $60,521
-43,230 Reduced 1.76%
2,415,728 $3.38 Million
Q4 2023

Feb 14, 2024

SELL
$0.85 - $1.12 $335,474 - $442,037
-394,676 Reduced 13.83%
2,458,958 $2.75 Million
Q3 2023

Nov 14, 2023

SELL
$0.98 - $1.46 $129,862 - $193,468
-132,513 Reduced 4.44%
2,853,634 $2.97 Million
Q2 2023

Aug 14, 2023

BUY
$1.27 - $1.95 $187,581 - $288,018
147,702 Added 5.2%
2,986,147 $3.82 Million
Q1 2023

May 15, 2023

BUY
$1.29 - $1.66 $111,305 - $143,229
86,283 Added 3.14%
2,838,445 $3.95 Million
Q4 2022

Feb 14, 2023

BUY
$1.26 - $1.51 $143 - $172
114 Added 0.0%
2,752,162 $3.58 Million
Q3 2022

Nov 14, 2022

SELL
$1.48 - $2.61 $4,851 - $8,555
-3,278 Reduced 0.12%
2,752,048 $4.07 Million

Others Institutions Holding BOLT

About Bolt Biotherapeutics, Inc.


  • Ticker BOLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,641,500
  • Market Cap $18.8M
  • Description
  • Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...
More about BOLT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.